Janney Montgomery Scott LLC Has $26.43 Million Holdings in Axon Enterprise, Inc $AXON

Janney Montgomery Scott LLC lifted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 10.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,920 shares of the biotechnology company’s stock after purchasing an additional 2,993 shares during the period. Janney Montgomery Scott LLC’s holdings in Axon Enterprise were worth $26,428,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Axon Enterprise by 15.9% during the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after purchasing an additional 175,890 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the period. Northern Trust Corp lifted its holdings in shares of Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares during the period. Finally, Jennison Associates LLC lifted its holdings in shares of Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $711.34 on Thursday. The firm’s 50-day moving average price is $757.95 and its 200-day moving average price is $705.01. Axon Enterprise, Inc has a 1-year low of $397.53 and a 1-year high of $885.91. The firm has a market capitalization of $55.84 billion, a P/E ratio of 175.64, a P/E/G ratio of 27.87 and a beta of 1.42. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the prior year, the business earned $1.20 earnings per share. The business’s quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the subject of a number of analyst reports. Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the stock an “overweight” rating in a research note on Friday, July 11th. Needham & Company LLC reissued a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a research note on Wednesday, September 24th. UBS Group reissued a “neutral” rating and set a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. Finally, Piper Sandler initiated coverage on shares of Axon Enterprise in a research note on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 target price for the company. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Insider Activity at Axon Enterprise

In other news, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares of the company’s stock, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the sale, the chief accounting officer directly owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,932 shares of company stock valued at $37,978,216 over the last quarter. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.